Prognostic Scoring Systems in CML - Improvement Impossible?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F15%3A33155103" target="_blank" >RIV/61989592:15110/15:33155103 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.4172/2329-6917.S1-001" target="_blank" >http://dx.doi.org/10.4172/2329-6917.S1-001</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.4172/2329-6917.S1-001" target="_blank" >10.4172/2329-6917.S1-001</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Prognostic Scoring Systems in CML - Improvement Impossible?

Popis výsledku v původním jazyce

Since introduction of oral chemotherapy in the treatment of CML there is a continual effort for estimation of prognosis including future response to the therapy. Despite the first efficient prognostic scoring systems were designed for the patients treated with busulfan or hydroxyurea and interferon-alpha, respectively, Sokal and Hasford (Euro) scores are used for the patients treated with tyrosine kinase inhibitors (TKI) nowadays with a very good predictive value. The EUTOS score - specifically designedfor the treatment with TKI - is (unlikely the previous scores) very easy to be counted, however, in some cohorts of patients failed to provide optimal predictive role for overall survival of patients. New strategies for CML prognostic score computationinclude implementation of newly designed statistic tools and end-points. On the other hand there is a simple possibility of designing the combination scores or including the early response to the treatment into the scoring system. However

Název v anglickém jazyce

Prognostic Scoring Systems in CML - Improvement Impossible?

Popis výsledku anglicky

Since introduction of oral chemotherapy in the treatment of CML there is a continual effort for estimation of prognosis including future response to the therapy. Despite the first efficient prognostic scoring systems were designed for the patients treated with busulfan or hydroxyurea and interferon-alpha, respectively, Sokal and Hasford (Euro) scores are used for the patients treated with tyrosine kinase inhibitors (TKI) nowadays with a very good predictive value. The EUTOS score - specifically designedfor the treatment with TKI - is (unlikely the previous scores) very easy to be counted, however, in some cohorts of patients failed to provide optimal predictive role for overall survival of patients. New strategies for CML prognostic score computationinclude implementation of newly designed statistic tools and end-points. On the other hand there is a simple possibility of designing the combination scores or including the early response to the treatment into the scoring system. However

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Leukemia

ISSN

2329-6917

e-ISSN

—

Svazek periodika

2015

Číslo periodika v rámci svazku

S1.001

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

3

Strana od-do

1-3

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—